Academic Journal
Elevated serotonin 1A receptor binding in borderline personality disorder co-morbid with major depressive episodes appears attributable to major depression alone.
| Τίτλος: | Elevated serotonin 1A receptor binding in borderline personality disorder co-morbid with major depressive episodes appears attributable to major depression alone. |
|---|---|
| Συγγραφείς: | Elizabeth Sublette M; Department of Psychiatry, Columbia University, NY, NY, USA; Molecular Imaging & Neuropathology Area, New York State Psychiatric Institute, NY, NY, USA. Electronic address: elizabeth.sublette@nyspi.columbia.edu., Byrnes A; Department of Psychiatry, Columbia University, NY, NY, USA; Molecular Imaging & Neuropathology Area, New York State Psychiatric Institute, NY, NY, USA., Todd Ogden R; Department of Psychiatry, Columbia University, NY, NY, USA; Molecular Imaging & Neuropathology Area, New York State Psychiatric Institute, NY, NY, USA; Department of Biostatistics, Mailman School of Public Health, Columbia University, NY, NY, USA., Zanderigo F; Department of Psychiatry, Columbia University, NY, NY, USA; Molecular Imaging & Neuropathology Area, New York State Psychiatric Institute, NY, NY, USA., Burke A; Molecular Imaging & Neuropathology Area, New York State Psychiatric Institute, NY, NY, USA., Oquendo MA; Psychiatry Department, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Stanley B; Department of Psychiatry, Columbia University, NY, NY, USA; Molecular Imaging & Neuropathology Area, New York State Psychiatric Institute, NY, NY, USA., John Mann J; Department of Psychiatry, Columbia University, NY, NY, USA; Molecular Imaging & Neuropathology Area, New York State Psychiatric Institute, NY, NY, USA; Department of Radiology, Columbia University, NY, NY, USA., Miller JM; Department of Psychiatry, Columbia University, NY, NY, USA; Molecular Imaging & Neuropathology Area, New York State Psychiatric Institute, NY, NY, USA. |
| Πηγή: | Journal of psychiatric research [J Psychiatr Res] 2026 Sep; Vol. 200, pp. 123-129. Date of Electronic Publication: 2026 May 15. |
| Τύπος έκδοσης: | Journal Article; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Pergamon Press Country of Publication: England NLM ID: 0376331 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-1379 (Electronic) Linking ISSN: 00223956 NLM ISO Abbreviation: J Psychiatr Res Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Oxford : Pergamon Press |
| Ιατρικοί όροι (MeSH): | Borderline Personality Disorder*/diagnostic imaging , Borderline Personality Disorder*/metabolism , Borderline Personality Disorder*/complications , Borderline Personality Disorder*/epidemiology , Receptor, Serotonin, 5-HT1A*/metabolism , Major Depressive Disorder*/diagnostic imaging , Major Depressive Disorder*/metabolism , Major Depressive Disorder*/complications , Major Depressive Disorder*/epidemiology , Brain*/diagnostic imaging , Brain*/metabolism, Pyridines/pharmacokinetics ; Piperazines/pharmacokinetics ; Bipolar Disorder/diagnostic imaging ; Bipolar Disorder/metabolism ; Bipolar Disorder/complications ; Humans ; Female ; Positron-Emission Tomography ; Male ; Adult ; Young Adult ; Middle Aged ; Comorbidity ; Psychiatric Status Rating Scales |
| Περίληψη: | Borderline personality disorder (BPD) is characterized by interpersonal dysfunction, emotional lability, impulsivity, and risk of self-injurious behaviors, and is frequently comorbid with mood disorders. Several BPD symptoms have been associated with altered serotonin (5-HT) system function. We sought to determine whether 5-HT 1A (5-HT (Copyright © 2026 Elsevier Ltd. All rights reserved.) |
| Competing Interests: | Declaration of competing interest Dr. Oquendo receives royalties from the Research Foundation for Mental Hygiene for the commercial use of the Columbia Suicide Severity Rating Scale. She serves as an advisor to Mind Medicine (pro bono), and Fundacion Jimenez Diaz. She reviews grants for Alkermes and her family formerly owned stock in Bristol Myers Squibb (sold March 2024). Dr. Mann receives royalites for commercial use of the C-SSRS from the Research Foundation for Mental Hygiene and from Columbia University for the Columbia Pathways App. Dr. Miller has received research support from Evexcia Therapeutics and AbbVie, unrelated to the current work. Dr. Burke receives royalties from the commercial use of the Columbia Suicide Severity Rating Scale. All other authors have no conflicts of interest to disclose. |
| Grant Information: | R01 MH040695 United States MH NIMH NIH HHS; P50 MH062185 United States MH NIMH NIH HHS; K08 MH001997 United States MH NIMH NIH HHS; K08 MH067015 United States MH NIMH NIH HHS; R01 MH048514 United States MH NIMH NIH HHS; K08 MH085061 United States MH NIMH NIH HHS; P50 MH090964 United States MH NIMH NIH HHS |
| Contributed Indexing: | Keywords: 5-HT1A; Bipolar disorder; Borderline personality disorder; Major depressive disorder; PET; Serotonin |
| Substance Nomenclature: | 112692-38-3 (Receptor, Serotonin, 5-HT1A) 0 (Pyridines) 0 (Piperazines) 71IH826FEG (N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide) |
| Entry Date(s): | Date Created: 20260522 Date Completed: 20260612 Latest Revision: 20260812 |
| Update Code: | 20260813 |
| PubMed Central ID: | PMC13371117 |
| DOI: | 10.1016/j.jpsychires.2026.05.028 |
| PMID: | 42173043 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1879-1379 |
|---|---|
| DOI: | 10.1016/j.jpsychires.2026.05.028 |